Fig. 5From: Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trialSurvival regarding the primary endpoint (all-cause death) and the secondary endpoint (cardiovascular death) stratified according to the tertile distribution of GAS6 in different renal function groups (based on eGFR)Back to article page